Currently out of the existing stock ratings of Martin Auster, 86 are a BUY (70.49%), 6 are a SELL (4.92%), 30 are a HOLD (24.59%).

Martin Auster

Work Performance Price Targets & Ratings Chart

Analyst Martin Auster, currently employed carries an average stock price target met ratio of 56.82% that have a potential upside of 23.41% achieved within 182 days. Previously, Martin Auster worked at CREDIT SUISSE.

Martin Auster’s has documented 262 price targets and ratings displayed on 26 stocks. The coverage was on the Healthcare sector.

Most recent stock forecast was given on BMRN, Biomarin Pharmaceutical at 18-Sep-2023.

Wall Street Analyst Martin Auster

Analyst best performing recommendations are on SLDB (SOLID BIOSCIENCES LLC).
The best stock recommendation documented was for SLDB (SOLID BIOSCIENCES LLC) at 5/14/2019. The price target of $90 was fulfilled within 1 day with a profit of $4.8 (5.06%) receiving and performance score of 50.63.

Average potential price target upside

of $31.86 (28.44%) on ALXN (ALEXION PHARMACEUTICALS).
of $25.06 (17.7%) on RARE (ULTRAGENYX).
of $24.86 (43.12%) on MYOK (MYOKARDIA).

ALXN Alexion Pharmaceuticals ALXO Alx Oncology Holdings ANAB AnaptysBio ARNA Arena Pharmaceuticals BMRN Biomarin Pharmaceutical ESPR Esperion Therapeutics ETTX Entasis Therapeutics Holdings FLXN Flexion Therapeutics INSM Insmed MYOK MyoKardia PTCT PTC Therapeutics RARE Ultragenyx SLDB Solid Biosciences LLC SPRB Spruce Biosciences SRPT Sarepta Therapeutics STOK Stoke Therapeutics UTHR United Therapeutics XLRN Acceleron Pharma OBSV ObsEva SA ONCE Spark Therapeutics GLTO Galecto RXDX Prometheus Biosciences INBX Inhibrx CVAC CureVac NV KURA Kura Oncology NTLA Intellia Therapeutics

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Hartaj Singh (OPPENHEIMER)